X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse ASTRAZENECA PHARMA with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs MYLAN (US) - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ASTRAZENECA PHARMA   MYLAN
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
MYLAN
Dec-14
ASTRAZENECA PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,2854,254-   
Low Rs6342,998-   
Sales per share (Unadj.) Rs189.61,456.2-  
Earnings per share (Unadj.) Rs-0.2175.4-  
Cash flow per share (Unadj.) Rs3.8282.4-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs68.6723.9-  
Shares outstanding (eoy) m25.00378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x5.12.5 203.3%   
Avg P/E ratio x-4,712.720.7 -22,801.8%  
P/CF ratio (eoy) x249.612.8 1,943.8%  
Price / Book Value ratio x14.05.0 279.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m23,9881,371,817 1.7%   
No. of employees `0001.625.0 6.2%   
Total wages/salary Rs m1,6050-   
Avg. sales/employee Rs Th3,040.222,039.1 13.8%   
Avg. wages/employee Rs Th1,029.20-   
Avg. net profit/employee Rs Th-3.32,655.0 -0.1%   
INCOME DATA
Net Sales Rs m4,740550,976 0.9%  
Other income Rs m92-3,212 -2.9%   
Total revenues Rs m4,832547,765 0.9%   
Gross profit Rs m-130137,030 -0.1%  
Depreciation Rs m10140,467 0.3%   
Interest Rs m023,766 0.0%   
Profit before tax Rs m-13969,586 -0.2%   
Minority Interest Rs m0-285 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m52,926 0.2%   
Profit after tax Rs m-566,374 -0.0%  
Gross profit margin %-2.724.9 -11.0%  
Effective tax rate %-3.74.2 -87.1%   
Net profit margin %-0.112.0 -0.9%  
BALANCE SHEET DATA
Current assets Rs m2,726484,381 0.6%   
Current liabilities Rs m2,435378,689 0.6%   
Net working cap to sales %6.119.2 32.1%  
Current ratio x1.11.3 87.5%  
Inventory Days Days7478 94.5%  
Debtors Days Days41107 38.0%  
Net fixed assets Rs m1,035127,467 0.8%   
Share capital Rs m5019,484 0.3%   
"Free" reserves Rs m9420-   
Net worth Rs m1,716273,890 0.6%   
Long term debt Rs m0409,164 0.0%   
Total assets Rs m4,1561,103,202 0.4%  
Interest coverage xNM3.9-  
Debt to equity ratio x01.5 0.0%  
Sales to assets ratio x1.10.5 228.3%   
Return on assets %-0.18.2 -1.5%  
Return on equity %-0.324.2 -1.2%  
Return on capital %013.6 0.0%  
Exports to sales %5.70-   
Imports to sales %6.50-   
Net fx Rs m-960-   
CASH FLOW
From Operations Rs m-872,426 -0.0%  
From Investments Rs m-146-57,117 0.3%  
From Financial Activity Rs m862-19,084 -4.5%  
Net Cashflow Rs m709-3,775 -18.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.37 Rs / USD

Compare ASTRAZENECA PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare ASTRAZENECA PHARMA With: ALEMBIC LTD  TORRENT PHARMA  PFIZER  WOCKHARDT LTD.  CADILA HEALTHCARE  



Today's Market

Sensex Ends 300 Points Lower; Metal and IT Stocks Witness Selling(Closing)

Share markets in India witnessed most of the selling pressure during closing hours and ended their trading session on a negative note.

Related Views On News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 212.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 32 m (down 212.1% YoY). Sales on the other hand came in at Rs 2 bn (up 35.1% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Nov 20, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - PANACEA BIOTECH COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS